Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva Seeds OTC Growth Synergies With Former Allergan Business

Executive Summary

Teva's opportunity to compete in the US OTC drug market now that the Allergan's generic nonprescription products are under its roof makes company "more excited" about the space "than we have ever been," says CEO Sigurdur Olaf Olaffson,


Related Content

Perrigo Glows From Mucinex Private Label Plan, Starboard Plug
Teva’s 'Key Ingredient' For Growth: Biosimilars
Heated Drug Pricing Debate Fanned By Election, Teva's Olafsson Says
Private Label Mucinex March Reaches Two Formulations
Teva Gets What It Wants – Allergan Generics, Not Mylan
PGT Healthcare Aims To Unlock Value Of Existing Portfolios


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts